trending Market Intelligence /marketintelligence/en/news-insights/trending/gypqohf6k4wwvyv9rzlvta2 content esgSubNav
In This List

DanDrit Biotech applies to list on Nasdaq

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


DanDrit Biotech applies to list on Nasdaq

DanDrit Biotech USA Inc. filed an application to list its common shares on the Nasdaq Capital Market following the acquisition of privately held Enochian Biopharma Inc.

The Danish biopharmaceutical company will change its name to Enochian BioSciences Inc. and relocate its headquarters to Los Angeles. It is currently listed on the OTC Pink market.

DanDrit specializes in developing immunotherapies for various types of cancer and is currently working on innovative treatments for HIV and colon cancer.